Alexander Luft

机构：Leningrad Regional Cancer Center

发表论文 71 篇 · 总被引 5463 次 · h-index 22

代表论文

• Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial (2021 · The Lancet · 被引 1509)
• Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study (2023 · Journal of Clinical Oncology · 被引 549)
• Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study (2022 · Journal of Clinical Oncology · 被引 448)
• IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). (2021 · Journal of Clinical Oncology · 被引 117)
• Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) (2020 · Lung Cancer · 被引 63)
• PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study (2021 · Journal of Thoracic Oncology · 被引 50)